OSIR Osiris Therapeutics, Inc. featured news, full reports, and detailed charts
Osiris Therapeutics, Inc. (OSIR) Wrap Up:
Osiris Therapeutics, Inc., a biotechnology company, commercializes stem cell products from adult bone marrow in the United States. It develops and markets products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas. The company’s products include Prochymal, which is in phase III clinical trials for the treatment of steroid refractory Graft versus Host Disease (GvHD), acute GvHD, and Crohn’s disease; in phase II clinical trials for the treatment of Type I diabetes and acute myocardial infarction; in preclinical stage for the treatment of acute radiation syndrome; and Chondrogen, a phase I/II clinical trial used for the treatment of osteoarthritis and the red...www.osiristx.com
158 Employees
Founded in 1992
Osiris Therapeutics, Inc. (OSIR:NASDAQ)
LAST $6.58 USD
CHANGE TODAY +0.10 1.54%
VOLUME 49.7K
As of 12:00 PM 11/20/09 All times are local (Market data by Reuters is delayed by at least 15 minutes).
Snapshot of Osiris Therapeutics, Inc. (OSIR)
|
OPEN
$6.49
|
PREVIOUS CLOSE
$6.48
|
|
|
DAY HIGH
$6.63
|
DAY LOW
$6.49
|
|
|
52 WEEK HIGH
12/2/08 - $21.65
|
52 WEEK LOW
11/3/09 - $5.35
|
|
|
MARKET CAP
215.6M
|
AVERAGE VOLUME 3 mo
122.4K
|
|
|
DILUTED EPS TTM
$-1.08
|
SHARES OUTSTANDING
32.8M
|
|
|
OSIR Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
related news
Stocks Rise on Higher Commodites, Merger News
09/08/2009 4:40 PM ET
Stocks Rise on Higher Commodites, Merger News
09/08/2009 4:40 PM ET
The Best Bets in Bionic Investing
05/21/2007 12:01 AM ET
Stocks Finish Mixed on Home Sales Drop
03/26/2007 4:35 PM ET
related news
Knight Ridder/Tribune - 11/20/2009 2:13 AM ET
OSIR Top Compensated Officers
Dr. Charles Randal Mills Ph.D.
Chief Executive Officer, President and Direct...
Age: 37
Total Annual Compensation: $688.8K
Mr. Philip R. Jacoby Jr.
Chief Financial Officer and Corporate Secreta...
Age: 58
Total Annual Compensation: $183.4K
Dr. Lode Debrabandere Ph.D.
Senior Vice President of Therapeutics
Age: 45
Total Annual Compensation: $314.9K
Dr. Michelle LeRoux Williams Ph.D.
Chief Scientific Officer
Age: 34
Total Annual Compensation: $295.0K
Executives, Board Directors
Compensation as of Fiscal Year 2008.
Key developments for Osiris Therapeutics, Inc. (OSIR)
Osiris Therapeutics Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2009
11/4/2009
Osiris Therapeutics Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2009. For the quarter, the company reported loss from operations of $7,174,000, loss from continuing operations, before income taxes of $7,040,000, loss from continuing operations of $6,802,000 or $0.21 diluted loss per share, net loss of $6,194,000 or $0.19 diluted loss per share on revenue from collaborative research agreements, government contract and royalties of $10,584,000 against loss from operations of $19,484,000, loss from continuing operations, before income taxes of $19,903,000, loss from continuing operations of $19,903,000 or $0.63 diluted loss per share, net income of $5,252,000 or $0.17 diluted per share on revenue from collaborative research agreements, government contract and royalties of $995,000 for the same period a year ago. For the nine months, the company reported loss from operations of $26,320,000, loss from continuing operations, before income taxes of $25,933,000, loss from continuing operations of $23,297,000 or $0.71 diluted loss per share, net loss of $1,116,000 or $0.03 diluted loss per share on revenue from collaborative research agreements, government contract and royalties of $33,779,000 against loss from operations of $56,724,000, loss from continuing operations, before income taxes of $57,524,000, loss from continuing operations of $57,524,000 or $1.81 diluted loss per share, net loss of $25,716,000 or $0.81 diluted loss per share on revenue from collaborative research agreements, government contract and royalties of $3,887,000 for the same period a year ago. Net cash provided by operating activities of $5,387,000, purchases of property and equipment of $181,000 against net cash used in operating activities of $46,603,000, purchases of property and equipment of $4,029,000 for the same period a year ago.
Osiris Therapeutics, Inc. expected to Report Fiscal Year 2009 Results on February 22, 2010. This event was calculated by Capital IQ (Created on November 4, 2009).
11/4/2009
Osiris Therapeutics, Inc. expected to Report Fiscal Year 2009 Results on February 22, 2010. This event was calculated by Capital IQ (Created on November 4, 2009).
Osiris Therapeutics, Inc., Q3 2009 Earnings Call, Nov--04-2009
10/23/2009
Osiris Therapeutics, Inc., Q3 2009 Earnings Call, Nov-04-2009
OSIR Competitors
| Company | Last | Change |
| Aastrom Biosciences Inc | $0.30 USD | -0.0082 |
| Advanced Cell Technology Inc | $0.10 USD | +0.0035 |
| Cytori Therapeutics Inc | $4.26 USD | 0.00 |
| StemCells Inc | $1.09 USD | 0.00 |
| Thermogenesis Corp | $0.62 USD | -0.0075 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | OSIR | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 5.3x |
|
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 2.7x |
|
|
OSIR |
||
|
OSIR transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent News About Osiris Therapeutics, Inc.
More news for OSIR
Osiris Therapeutics Reports Third Quarter 2009 Financial Results
OSIRIS THERAPEUTICS, INC. Condensed Statements of Operations Unaudited Amounts in thousands, except per share data   Three Months Ended September 30, Nine Months Ended September 30, 2009  2008 2009  2008  Revenue from collaborative research agreements, government contract and royalties $ 10,584 $ 995 $ ...Click here to read the whole Article (external link)
OSIRIS THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
Show all filings for OSIRIS THERAPEUTICS, INC. | Request a Trial to NEW EDGAR Online Pro Form 8-K for OSIRIS THERAPEUTICS, INC. 4-Nov-2009Results of Operations and Financial Condition, Financial Statements and Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information ...Click here to read the whole Article (external link)
Osiris Therapeutics loses $6M in 3Q
ONLINE: home | business news | small business | sales & marketing | real estate | events | community | careers | city guide | advertise | about us | rss PRINT: subscribe | renew | advertise | book of lists | business intelligence | classifieds | ...Click here to read the whole Article (external link)
Q3 2009 OSIRIS THERAPEUTICS INC Earnings Release - Before Market Open
Earnings Announcements for Wednesday, November 4CompanySymbolTimeConferenceCall99 CENTS OnlyNDNAfter Market CloseAdept TechnologyADEPAfter Market CloseAffymax, Inc.AFFYBefore Market OpenAgilysys, Inc.AGYSBefore Market OpenAgrium Inc.AGUBefore Market OpenListenAlamo GroupALGAfter Market CloseALGOMA CENTRAL CORPALC.TOTime Not SuppliedALLIANCE BANKSHARES CORPABVAAfter Market CloseAllied Motion Technologies, Inc.AMOTTime Not SuppliedListenAlmost FamilyAFAMBefore Market OpenAlnylam PharmaceuticalsALNYAfter Market CloseListenAlon USA Energy Inc.ALJAfter Market CloseAlterian plcALN.LTime Not SuppliedAlvarionALVRBefore Market OpenListenAmbac Financial GroupABK08:30 am ETListenAmbassadors International, Inc.AMIEAfter Market CloseAmdocs LimitedDOX...Click here to read the whole Article (external link)
New Star Analyst Rankings for Osiris Therapeutics, Inc.
Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Copyright © 1999-2003, StarMine Corp. All rights reserved.StarMine Corp. derives analyst ratings from estimate and recommendation data supplied by Thomson Financial.Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). International historical chart data, daily updates, fund summary, fund performance, dividend data and...Click here to read the whole Article (external link)
OSIRIS THERAPEUTICS, INC. Financials
Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Fundamental company data provided by Capital IQ. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. Real-...Click here to read the whole Article (external link)
OSIRIS THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations. Forward-Looking Information This Quarterly Report includes "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events, future revenues or performance, capital expenditures, compensation arrangements, financing needs, plans or intentions relating to acquisitions, business trends and other information that is not historical information and, in particular, may appear under the headings "Risk Factors" in our Annual Report on Form 10-K under Part I-Item 1A, "Part II-Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations" and the other documents we file with the United States Securities and Exchange Commission, or SEC, including, among others, this and other of our quarterly reports on Form 10-Q and any amendments thereto. When used in this Quarterly Report, the words estimates, expects, anticipates, projects, plans, intends, believes, forecasts and variations of such words or similar expressions are intended to identify forward-looking statements. Examples of forward-looking statements include, but are not limited to, statements regarding the following: our product development efforts; our clinical trials and anticipated regulatory requirements; the success of our product candidates in development; status of the regulatory process for our biologic drug candidates; implementation of our corporate strategy; our financial performance; our product research and development activities and projected expenditures, including our anticipated timeline and clinical strategy for mesenchymal stem cells and biologic drug candidates (including the anticipated timeline and clinical strategy for Prochymal and Chondrogen); our cash needs; pat...Click here to read the whole Article (external link)
Would you like to leave a comment about Osiris Therapeutics, Inc. OSIR
Find out what social network information about Osiris Therapeutics, Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Osiris Therapeutics, Inc. there is more great information available at Realpennies.com